SCHEMBL20399786

SCHEMBL20399786

CN(C)CC1CN(C(=O)O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 3/20 0.34
OPRD1 P41143 2/20 0.34
KDM4E B2RXH2 1/20 0.32
MITF O75030 1/20 0.31
HSP90AA1 P07900 1/20 0.31
METAP1 P53582 3/20 0.31
CCR6 P51684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20399751 1.00 OPRK1 (0.34) OPRK1OPRD1KDM4EMITFHSP90AA1
SCHEMBL21528222 0.80 JAK2 (0.42) KDM4E
SCHEMBL28196771 0.77 POLB (0.33)
SCHEMBL12142325 0.76 METAP1 (0.33) MITFHSP90AA1METAP1CCR6
SCHEMBL3169586 0.74 FAAH (0.42)
SCHEMBL9052963 0.72 TACR3 (0.43) KDM4E
SCHEMBL15352654 0.72 TACR3 (0.43) KDM4E
SCHEMBL21081462 0.72 LMNA (0.35)
SCHEMBL22634130 0.72 LMNA (0.35)
SCHEMBL504706 0.72 LMNA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3570838-B1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY INC (US) 2024-06-05 EP disclosed
US-20240043387-A1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY INC (US) 2024-02-08 US disclosed
US-11319290-B2 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same MEBIAS DISCOVERY, INC. (US) 2022-05-03 US disclosed
US-20210101868-A1 Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using Same MEBIAS DISCOVERY, INC. 2021-04-08 US disclosed
US-10836728-B2 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same MEBIAS DISCOVERY, INC. (US) 2020-11-17 US disclosed
US-20190337901-A1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY, INC. 2019-11-07 US disclosed
WO-2018136546-A1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME MEBIAS DISCOVERY LLC (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210101868-A1 Substituted 3-Dialkylaminomethyl-Piperidin-4-yl-Benzamides and Methods of Making and Using Same ALKBH5, ALKBH2, ALKBH3 OPRK1 13/4885OPRD1 388/4885KDM4E 103/4885
US-20240043387-A1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME ALKBH5, ALKBH2, ALKBH3 OPRK1 13/4885OPRD1 388/4885KDM4E 103/4885
US-10836728-B2 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same ALKBH5, ALKBH2, ALKBH3 OPRK1 13/4885OPRD1 388/4885KDM4E 103/4885
US-20190337901-A1 SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME ALKBH5, ALKBH2, ALKBH3 OPRK1 13/4885OPRD1 388/4885KDM4E 103/4885
US-11319290-B2 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same ALKBH5, ALKBH2, ALKBH3 OPRK1 13/4885OPRD1 388/4885KDM4E 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.